Healthcare provider profile · identity verified

Peter B Jalbuena, M.D.

Internal Medicine · BURBANK, CA · NPI 1669705406

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1159	398
Losartan Potassium	Losartan Potassium	722	240
Amlodipine Besylate	Amlodipine Besylate	705	253
Metformin Hcl	Metformin Hcl	501	167
Lisinopril	Lisinopril	444	151
Rosuvastatin Calcium	Rosuvastatin Calcium	391	149
Glipizide	Glipizide	348	123
Allopurinol	Allopurinol	336	111
Jardiance	Empagliflozin	291	97
Atenolol	Atenolol	251	91
Simvastatin	Simvastatin	247	77
Levothyroxine Sodium	Levothyroxine Sodium	231	76
Albuterol Sulfate Hfa	Albuterol Sulfate	195	100
Gabapentin	Gabapentin	176	70
Terazosin Hcl	Terazosin Hcl	171	54
Hydrochlorothiazide	Hydrochlorothiazide	165	57
Omeprazole	Omeprazole	160	69
Pantoprazole Sodium	Pantoprazole Sodium	160	47
Metoprolol Tartrate	Metoprolol Tartrate	158	57
Meloxicam	Meloxicam	150	83
Tamsulosin Hcl	Tamsulosin Hcl	150	54
Pradaxa	Dabigatran Etexilate Mesylate	132	39
Alendronate Sodium	Alendronate Sodium	114	40
Triamcinolone Acetonide	Triamcinolone Acetonide	114	59
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	109	37
Hydralazine Hcl	Hydralazine Hcl	101	38
Clopidogrel	Clopidogrel Bisulfate	97	34
Fluticasone Propionate	Fluticasone Propionate	95	44
Metformin Hcl Er	Metformin Hcl	95	33
Finasteride	Finasteride	94	35
Tramadol Hcl	Tramadol Hcl	91	36
Lactulose	Lactulose	90	34
Bisoprolol Fumarate	Bisoprolol Fumarate	85	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	84	28
Lidocaine	Lidocaine	80	41
Potassium Chloride	Potassium Chloride	80	29
Hydrocortisone	Hydrocortisone	74	45
Montelukast Sodium	Montelukast Sodium	72	25
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	70	21
Furosemide	Furosemide	69	30
Spiriva Respimat	Tiotropium Bromide	65	18
Mirtazapine	Mirtazapine	64	28
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	62	17
Lorazepam	Lorazepam	61	15
Pravastatin Sodium	Pravastatin Sodium	61	22
Trazodone Hcl	Trazodone Hcl	60	30
Colchicine	Colchicine	58	28
Carvedilol	Carvedilol	57	22
Ozempic	Semaglutide	55	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	54	16
Arexvy	Rsvpref3 Antigen/As01e/Pf	53	53
Famotidine	Famotidine	52	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	18
Humulin N	Insulin Nph Human Isophane	49	18
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	48	18
Pioglitazone Hcl	Pioglitazone Hcl	48	17
Lovastatin	Lovastatin	46	13
Tradjenta	Linagliptin	46	25
Duloxetine Hcl	Duloxetine Hcl	44	19
Wixela Inhub	Fluticasone Propion/Salmeterol	44	19
Levetiracetam	Levetiracetam	42	suppressed
Azelastine Hcl	Azelastine Hcl	39	19
Alvesco	Ciclesonide	35	21
Breyna	Budesonide/Formoterol Fumarate	35	18
Sertraline Hcl	Sertraline Hcl	35	13
Ezetimibe	Ezetimibe	34	13
Fenofibrate	Fenofibrate	34	14
Humulin N Kwikpen	Insulin Nph Human Isophane	34	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	33	33
Nifedipine Er	Nifedipine	33	17
Xarelto	Rivaroxaban	30	suppressed
Benazepril Hcl	Benazepril Hcl	29	suppressed
Metoprolol Succinate	Metoprolol Succinate	29	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	27	26
Humulin R	Insulin Regular, Human	25	11
Alprazolam	Alprazolam	24	suppressed
Sitagliptin	Sitagliptin	24	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Glimepiride	Glimepiride	23	12
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Terbinafine Hcl	Terbinafine Hcl	23	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	23	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Nitroglycerin	Nitroglycerin	21	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Eliquis	Apixaban	20	suppressed
Estradiol	Estradiol	20	11
Fluocinonide	Fluocinonide	20	11
Propranolol Hcl	Propranolol Hcl	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Azithromycin	Azithromycin	19	19
Clonidine Hcl	Clonidine Hcl	19	suppressed
Febuxostat	Febuxostat	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Cephalexin	Cephalexin	17	15
Myrbetriq	Mirabegron	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Nystatin	Nystatin	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	15	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	15	15
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Dilt-Xr	Diltiazem Hcl	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	14
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	14	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Primidone	Primidone	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error